Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results and a business update for the period ended June 30, 2026. The company reached agreement with the FDA on key elements of its planned registrational Phase 3 trial of belapectin in advanced MASH cirrhosis with portal hypertension, including a composite liver outcome primary endpoint, blinded central endoscopy review and a single 2 mg/kg LBM dose. Protocol submission is anticipated in 3Q 2026.New NAVIGATE Phase 2b/3 analyses were presented at EASL and published in Hepatology and Gastro Hep Advances. Chairman Richard Uihlein converted approximately $105.8 million of principal and accrued interest into 34.4 million shares, eliminating that debt. Q2 R&D was $2.1 million, G&A $1.8 million, and net loss applicable to common stockholders was $9.2 million ($0.14 per share). Cash was $13.2 million, with sufficient liquidity projected through June 2027 and $10 million remaining on a credit line.

Galectin Therapeutics (NASDAQ:GALT) hosted a virtual key opinion leader (KOL) event to discuss belapectin as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, a population the speakers described as having substantial un

Reported Tuesday, Jun 23 - 8:08am EDT (TheFly subscription required to read more.)

Reported Wednesday, May 27 - 9:11am EDT (TheFly subscription required to read more.)

Reported Tuesday, Feb 18 - 8:18am EST (TheFly subscription required to read more.)

FDA accepted Galectin’s endpoint and central endoscopy review for belapectin Phase 3. The company plans protocol filing in Q3 2026.

Galectin Therapeutics (NASDAQ:GALT) reported publication of Phase 2b NAVIGATE trial results for galectin-3 inhibitor belapectin in Journal of Hepatology. The study in patients with MASH cirrhosis and portal hypertension showed belapectin 2 mg/kg reduced new esophageal varices numerically versus placebo, with statistical significance in the per-protocol population and supportive fibrosis/portal hypertension biomarkers, alongside a favorable safety profile.

Net loss narrowed to $31.0M from $47.2M as R&D fell to $14.3M. Why it matters: Galectin says cash plus a $10M credit line funds operations through April 2027.

Galectin Therapeutics (NASDAQ: GALT) reported Q3 2025 results and a clinical update on belapectin from the NAVIGATE trial presented at AASLD. The company submitted the NAVIGATE data package to the FDA and expects feedback by year-end. Key 18-month biomarker findings showed reductions in liver stiffness (FibroScan), ELF, PRO-C3, YKL-40, and improvements in Baveno VII portal hypertension categories, with the 2 mg/kg dose showing a shift to no/low-risk CSPH (42.0% to 56.8%).Q3 cash was $11.5M, a $10M chairman line of credit was added July 8, 2025, R&D was $2.6M, G&A $1.6M, and net loss was $8.2M (−$0.13/share).

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2025 financial results and provided updates on their NAVIGATE trial for belapectin in MASH cirrhosis patients. The company ended Q2 with $13.8 million in cash and secured an additional $10 million credit line from its chairman in July 2025.Key financial metrics include a reduced net loss of $7.6 million ($0.12 per share) compared to $12.4 million in Q2 2024, and significantly lower R&D expenses of $3.3 million vs $9.8 million year-over-year. The company presented promising NAVIGATE trial results at EASL 2025, showing sustained efficacy in reducing liver stiffness and fewer patients experiencing clinically meaningful worsening in the belapectin arm.

Latest trial data reveals significant liver fibrosis improvement with belapectin treatment. Company reports $7.4M cash position. See complete Fibroscan results.

Galectin Therapeutics (NASDAQ:GALT) presented significant results from their NAVIGATE trial for belapectin at EASL 2025 Congress. The trial evaluated belapectin, a galectin-3 inhibitor, in 287 patients with MASH cirrhosis and portal hypertension. The study demonstrated that belapectin at 2 mg/kg significantly reduced new varices by 49.3% compared to placebo (p=0.04) at 18 months in the per-protocol population. The drug also showed significant improvement in liver stiffness measurements, with the 2mg/kg dose outperforming placebo by 66% (p=0.02). The safety profile remained encouraging, with adverse events comparable to placebo and no drug-related serious adverse events reported. The trial results support belapectin's potential as a treatment for MASH cirrhosis patients with portal hypertension.

Key NAVIGATE trial data reveals 68% reduction in MASH complications. $47.2M invested in R&D advances belapectin program. Q2 2025 biomarker data upcoming. Full analysis inside.

Galectin's belapectin achieves significant reduction in liver varices for MASH cirrhosis patients, addressing critical unmet need in 3M U.S. adults.

Key clinical data reveals significant varices reduction in per-protocol analysis, though primary endpoint falls short. Full safety profile and additional efficacy data expected in 2025.